{"id":"rts-s-as01","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Fever"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine works by introducing a weakened form of the parasite to the body, which triggers an immune response and the production of antibodies that can recognize and neutralize the parasite. This provides long-term protection against malaria, particularly in areas where the disease is common.","oneSentence":"RTS,S/AS01 is a vaccine that protects against malaria by stimulating the body to produce antibodies against the Plasmodium falciparum parasite.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:05.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria prevention in children"}]},"trialDetails":[{"nctId":"NCT04327440","phase":"","title":"RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2020-02-04","conditions":"Malaria, Malaria Vaccine, Insecticide-treated Bednets","enrollment":1691},{"nctId":"NCT02251704","phase":"PHASE4","title":"Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-22","conditions":"Malaria, Malaria Vaccines","enrollment":54115},{"nctId":"NCT05041556","phase":"","title":"Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine","status":"RECRUITING","sponsor":"Kintampo Health Research Centre, Ghana","startDate":"2021-10-18","conditions":"Malaria","enrollment":9280},{"nctId":"NCT03281291","phase":"","title":"Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-11-19","conditions":"Malaria","enrollment":1500},{"nctId":"NCT03806465","phase":"","title":"Malaria Vaccine Pilot Evaluation","status":"COMPLETED","sponsor":"Rafiq OKINE","startDate":"2019-02-25","conditions":"Malaria,Falciparum, Feasibility, Safety","enrollment":30124},{"nctId":"NCT04319380","phase":"PHASE3","title":"Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2020-04-01","conditions":"Malaria,Falciparum, Child, Only","enrollment":5098},{"nctId":"NCT06450379","phase":"","title":"Impact of Vaccines on Antimicrobial Microbial Resistance","status":"COMPLETED","sponsor":"Malawi Liverpool Wellcome Programme","startDate":"2021-03-15","conditions":"Vaccine","enrollment":13200},{"nctId":"NCT06424002","phase":"PHASE4","title":"The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children","status":"NOT_YET_RECRUITING","sponsor":"Kamuzu University of Health Sciences","startDate":"2024-06-01","conditions":"Malaria,Falciparum","enrollment":5400},{"nctId":"NCT03276962","phase":"PHASE2","title":"Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-28","conditions":"Malaria","enrollment":1500},{"nctId":"NCT03143218","phase":"PHASE3","title":"Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-04-17","conditions":"Malaria,Falciparum, Children, Only","enrollment":5920},{"nctId":"NCT02992119","phase":"PHASE2","title":"Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-06-04","conditions":"Malaria Vaccine","enrollment":193},{"nctId":"NCT03162614","phase":"PHASE2","title":"Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-24","conditions":"Malaria","enrollment":154},{"nctId":"NCT03824236","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-02-05","conditions":"Malaria","enrollment":61},{"nctId":"NCT00380393","phase":"PHASE2","title":"Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-03","conditions":"Malaria","enrollment":894},{"nctId":"NCT02252640","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-01","conditions":"Plasmodium Falciparum Malaria","enrollment":48},{"nctId":"NCT01883609","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2013-09","conditions":"Plasmodium Falciparum Malaria","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":357,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RTS,S/AS01","genericName":"RTS,S/AS01","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Biologic","firstApprovalDate":"","aiSummary":"RTS,S/AS01 is a vaccine that protects against malaria by stimulating the body to produce antibodies against the Plasmodium falciparum parasite. Used for Malaria prevention in children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}